Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 23

1.

Antiretroviral adherence and pharmacokinetics: review of their roles in sustained virologic suppression.

Pham PA.

AIDS Patient Care STDS. 2009 Oct;23(10):803-7. doi: 10.1089/apc.2008.0269. Review.

PMID:
19795999
2.

Lopinavir/ritonavir: a review of its use in the management of HIV infection.

Cvetkovic RS, Goa KL.

Drugs. 2003;63(8):769-802. Review.

PMID:
12662125
3.

Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.

Van Vaerenbergh K.

Verh K Acad Geneeskd Belg. 2001;63(5):447-73. Review.

PMID:
11813503
4.
5.

Saquinavir: a review of its use in boosted regimens for treating HIV infection.

Plosker GL, Scott LJ.

Drugs. 2003;63(12):1299-324. Review.

PMID:
12790697
6.

Pharmacokinetics and pharmacodynamics of boosted once-daily darunavir.

Kakuda TN, Brochot A, Tomaka FL, Vangeneugden T, Van De Casteele T, Hoetelmans RM.

J Antimicrob Chemother. 2014 Oct;69(10):2591-605. doi: 10.1093/jac/dku193. Epub 2014 Jun 20. Review.

PMID:
24951533
7.
8.

Efavirenz.

Maggiolo F.

Expert Opin Pharmacother. 2007 Jun;8(8):1137-45. Review.

PMID:
17516877
9.

Darunavir: a review of its use in the management of HIV infection in adults.

McKeage K, Perry CM, Keam SJ.

Drugs. 2009;69(4):477-503. doi: 10.2165/00003495-200969040-00007. Review.

PMID:
19323590
10.

Minimizing resistance consequences after virologic failure on initial combination therapy: a systematic overview.

Bartlett JA, Buda JJ, von Scheele B, Mauskopf JA, Davis EA, Elston R, King MS, Lanier ER.

J Acquir Immune Defic Syndr. 2006 Mar;41(3):323-31. Review. Erratum in: J Acquir Immune Defic Syndr. 2006 Nov 1;43(3):381.

PMID:
16540933
11.

Combination of protease inhibitors for the treatment of HIV-1-infected patients: a review of pharmacokinetics and clinical experience.

van Heeswijk RP, Veldkamp A, Mulder JW, Meenhorst PL, Lange JM, Beijnen JH, Hoetelmans RM.

Antivir Ther. 2001 Dec;6(4):201-29. Review.

PMID:
11878403
12.

Pharmacological and therapeutic properties of ritonavir-boosted protease inhibitor therapy in HIV-infected patients.

Zeldin RK, Petruschke RA.

J Antimicrob Chemother. 2004 Jan;53(1):4-9. Epub 2003 Dec 4. Review.

PMID:
14657084
13.

Pharmacokinetics, efficacy, and safety of darunavir/ritonavir 800/100 mg once-daily in treatment-naïve and -experienced patients.

Boffito M, Miralles D, Hill A.

HIV Clin Trials. 2008 Nov-Dec;9(6):418-27. doi: 10.1310/hct0906-418. Review. Erratum in: HIV Clin Trials. 2009 Mar-Apr;10(2):vi. Dosage error in published abstract; MEDLINE/PubMed abstract corrected.

PMID:
19203907
14.
15.

Once-daily administration of antiretrovirals: pharmacokinetics of emerging therapies.

Taburet AM, Paci-Bonaventure S, Peytavin G, Molina JM.

Clin Pharmacokinet. 2003;42(14):1179-91. Review.

PMID:
14606928
16.

Impact of once- and twice-daily dosing regimens on adherence and overall safety.

Hawkins T.

AIDS Read. 2004 Jun;14(6):320-2, 324, 329-31, 334-6. Review.

PMID:
15243968
17.

Paradoxes of adherence and drug resistance to HIV antiretroviral therapy.

Bangsberg DR, Moss AR, Deeks SG.

J Antimicrob Chemother. 2004 May;53(5):696-9. Epub 2004 Mar 24. Review.

PMID:
15044425
18.

Adherence-resistance relationships to combination HIV antiretroviral therapy.

Bangsberg DR, Kroetz DL, Deeks SG.

Curr HIV/AIDS Rep. 2007 May;4(2):65-72. Review.

PMID:
17547827
19.

Impact of disease, drug and patient adherence on the effectiveness of antiviral therapy in pediatric HIV.

Piana C, Danhof M, Della Pasqua O.

Expert Opin Drug Metab Toxicol. 2017 May;13(5):497-511. doi: 10.1080/17425255.2017.1277203. Epub 2017 Jan 23. Review.

PMID:
28043170
20.

HIV treatment adherence, drug resistance, virologic failure: evolving concepts.

Nachega JB, Marconi VC, van Zyl GU, Gardner EM, Preiser W, Hong SY, Mills EJ, Gross R.

Infect Disord Drug Targets. 2011 Apr;11(2):167-74. Review.

Supplemental Content

Support Center